PolyPeptide’s mission is to help customers develop products, secure regulatory approvals and successfully launch and commercialize their products in the market. Building on its values of “Innovation”, “Excellence” and “Trust”, PolyPeptide aims to be the preferred long-term partner for its customers, who typically expect their CDMO partners to have deep scientific knowledge, technical expertise and operational experience, demonstrating a relentless focus on quality and a high delivery performance.

Growth strategy

PolyPeptide sees its regional presence in Europe, the United States of America and India, its deep process development and manufacturing capabilities with over 1’000 distinct therapeutic peptides manufactured, and its culture of flexibility and responsiveness as competitive advantages.

As a multinational company with 1,273 employees at the end of 2023, PolyPeptide fosters an agile, open and collaborative work environment. It continuously develops its organization and shares best practices across the Group. Attracting and retaining qualified and engaged talent is essential for PolyPeptide to implement its growth strategy. ,

The strengths of PolyPeptide are reflected in its rich portfolio of custom and commercial projects with large exposure to metabolic diseases and the growth opportunities related to innovative therapies to treat diabetes and obesity (GLP-1).

To meet the increasing demand for manufactured volumes, PolyPeptide invests in the advancement of its manufacturing processes for enhanced throughput and sustainability, while at the same time expanding its manufacturing infrastructure.

Its goal is to be the most innovative peptides CDMO, strengthening competitive advantages in 1) superior pipeline development capabilities, 2) innovation focused on green chemistry and industrial manufacturing, and 3) capacity expansion leveraging the potential for modularity.

As part of its strategy, PolyPeptide continues to advance its capacity expansion roadmap, adding manufacturing capacity across the multi-site network. Through modular design, it strives for speed and flexibility, providing customers with additional options to support their supply chain and growth strategies.

PolyPeptide provides its offering with a “start here – stay here” philosophy, covering the entire life cycle of a drug, starting with the customer’s pre-clinical development projects, followed by clinical phases through to commercialization. As a result, its customer relationships are often strategic and long-term by nature.

The Group’s activities are subject to current Good Manufacturing Practices (cGMP) to assure the quality of its services and products at every stage, from raw material procurement, testing, and storage through to production, packaging, testing, releasing and finally delivery of the product to the customer.

As such, PolyPeptide also adheres to strict requirements related to the protection of the Environment, Health and Safety (EHS). It follows an integrated approach towards the management of environmental, social and governance (ESG) topics and follows fundamental principles of business ethics, corporate responsibility and compliance. The integration of relevant criteria into its strategy, operations and enterprise risk management framework  meets PolyPeptide’s business needs and stakeholder expectations.